Not too excited? Thank your endocannabinoids.
Neuron. 2006 Aug 17;51(4):393-5.
Please login to recommend the paper.
To make a comment you must login or register.
I think it would be worthwhile to look at the brain of older people who have used marijuana chronically and compare it with the brain of age-matched people who never used it. This simple comparison could throw added light on whether cannabis could help people with Alzheimer disease.
The research is very interesting and important. In Los Angeles, California, use of medical cannabis is encountered working in the field with adolescents or young adults. There is indeed controversy since hidden side effects include perceptual and family disorders. Those also need consideration at the psychosocial level.
At the neuronal level, cannabinoid research also needs to rule out an effect of cannabinoids on reducing prion fibrils (see Colin et al., 1999) or neurogenesis (La Spada, 2005). Neuroendocrine effects, prolactin release, gonadal atrophy, and tumor genesis need attention when studying cannabinoids.
Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE.
Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins.
J Neurosci. 1999 Feb 1;19(3):928-39.
La Spada AR.
Huntington's disease and neurogenesis: FGF-2 to the rescue?.
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17889-90.
Cannabinoid agonist is shown to have a thermal hyperalgesia effect in inflammatory pain involving the sensory pathways and activation of the calcineurin (Nathaniel et al., 2006). The role of sensory inhibition, anhedonia, and known effects of calcineurin in psychosis also need consideration.
Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN, Hargreaves KM.
Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons.
J Biol Chem. 2006 Oct 27;281(43):32879-90. Epub 2006 Sep 5